These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever. Jun HX; Zhixiang S; Chun W; Reksodiputro AH; Ranuhardy D; Tamura K; Matsumoto T; Lee DG; Purushotaman SV; Lim V; Ahmed A; Hussain Y; Chua M; Ong A; Liu CY; Hsueh PR; Lin SF; Liu YC; Suwangool P; Jootar S; Picazo JJ Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S128-32; discussion S133-40. PubMed ID: 16253480 [No Abstract] [Full Text] [Related]
4. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group. Tamura K Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072 [TBL] [Abstract][Full Text] [Related]
5. Relevant aspects in the Infectious Diseases Society of America (IDSA) guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Zinner SH Int J Hematol; 1998 Oct; 68 Suppl 1():S31-4. PubMed ID: 9838742 [No Abstract] [Full Text] [Related]
6. From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Hughes WT; Armstrong D; Bodey GP; Feld R; Mandell GL; Meyers JD; Pizzo PA; Schimpff SC; Shenep JL; Wade JC J Infect Dis; 1990 Mar; 161(3):381-96. PubMed ID: 2179420 [No Abstract] [Full Text] [Related]
7. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy? Klastersky J J Antimicrob Chemother; 2009 May; 63 Suppl 1():i14-5. PubMed ID: 19372173 [TBL] [Abstract][Full Text] [Related]
8. European experience of timentin in combination with aminoglycosides as empirical treatment in febrile neutropenic patients. Croydon E; Weerts D Chemioterapia; 1987 Jun; 6(2 Suppl):405-7. PubMed ID: 3334585 [No Abstract] [Full Text] [Related]
9. Empirical therapy of infections in neutropenic patients. Gaya H Br J Haematol; 1998 May; 101 Suppl 1():5-9. PubMed ID: 9607734 [No Abstract] [Full Text] [Related]
10. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why monotherapy? Williams KJ J Antimicrob Chemother; 2009 May; 63 Suppl 1():i18-20. PubMed ID: 19372175 [TBL] [Abstract][Full Text] [Related]
11. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Fever and neutropenia: the early years. Bodey GP J Antimicrob Chemother; 2009 May; 63 Suppl 1():i3-13. PubMed ID: 19372179 [TBL] [Abstract][Full Text] [Related]
12. Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Link H; Böhme A; Cornely OA; Höffken K; Kellner O; Kern WV; Mahlberg R; Maschmeyer G; Nowrousian MR; Ostermann H; Ruhnke M; Sezer O; Schiel X; Wilhelm M; Auner HW; ; Ann Hematol; 2003 Oct; 82 Suppl 2():S105-17. PubMed ID: 13680173 [TBL] [Abstract][Full Text] [Related]
13. Empiric therapy for infections in the febrile, neutropenic, compromised host. Giamarellou H Med Clin North Am; 1995 May; 79(3):559-80. PubMed ID: 7752729 [TBL] [Abstract][Full Text] [Related]
14. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Where do we go from here? Pizzo PA J Antimicrob Chemother; 2009 May; 63 Suppl 1():i16-7. PubMed ID: 19372174 [TBL] [Abstract][Full Text] [Related]